Complex analysis of the p53 tumor suppressor in lung carcinoma

J 2016

Complex analysis of the p53 tumor suppressor in lung carcinoma

ŠMARDOVÁ, Jana; Květoslava LIŠKOVÁ; Barbora RAVČUKOVÁ; Jitka MALČÍKOVÁ; Jitka HAUSNEROVÁ et. al.

Základní údaje

Originální název

Complex analysis of the p53 tumor suppressor in lung carcinoma

Název česky

Komplexní analýza nádorového supresoru p53 u plicního karcinomu

Autoři

Vydání

Oncology Reports, National Hellenic Research Foundation, 2016, 1021-335X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10601 Cell biology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.662

Kód RIV

RIV/00216224:14310/16:00089204

Organizační jednotka

Přírodovědecká fakulta

DOI

https://doi.org/10.3892/or.2015.4533

UT WoS

000368228900075

EID Scopus

2-s2.0-84955450564

Klíčová slova česky

plicní adenokarcinom; nádorový supresor p53; FASAY; FISH; mutace TP53

Klíčová slova anglicky

lung adenocarcinoma; p53 tumor suppressor; FASAY; FISH; TP53 mutation

Štítky

AKR, EL OK, podil

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 2. 2018 11:26, prof. RNDr. Jan Šmarda, CSc.

Anotace

V originále

Lung cancer is the leading cause of cancer-related deaths worldwide. Mutations of the TP53 gene occur very frequently in lung carcinomas and they play an important role in both oncogenic transformation of lung epithelial cells and lung carcinoma progression. We determined the TP53 status in 42 samples of squamous cell lung carcinoma (SQCC) and 56 samples of lung adenocarcinoma (AC) by the functional analysis FASAY and its variant called split assay. Altogether, we detected 64 TP53 mutations in 63 patients and analyzed them by cDNA and gDNA sequencing. The TP53 mutations were found in 76.2% (32/42) of SQCC cases, and 55.4% (31/56) of ACs. Immunoblotting revealed the p53 protein accumulation in 18 samples (42.9%) among SQCC cases and 19 samples (33.9%) among AC cases. Using fluorescence in situ hybridization we detected loss of the TP53-specific 17p13.3 locus in 23 from 41 analyzed SQCC samples (56.1%) and in 20 from 54 analyzed AC samples (37.0%). We did not find any statistically significant differences in overall and disease-free survival in relation to TP53 status.

Citovat

ŠMARDOVÁ, Jana; Květoslava LIŠKOVÁ; Barbora RAVČUKOVÁ; Jitka MALČÍKOVÁ; Jitka HAUSNEROVÁ; Miluše SVITÁKOVÁ; Renata HRABÁLKOVÁ; Lenka ZLÁMALÍKOVÁ; Kateřina STAŇO KOZUBÍK; Ivona BLAHÁKOVÁ; Jana ŠPELDOVÁ; Jiří JARKOVSKÝ a Jan ŠMARDA. Complex analysis of the p53 tumor suppressor in lung carcinoma. Oncology Reports. National Hellenic Research Foundation, 2016, roč. 35, č. 3, s. 1859-1867. ISSN 1021-335X. Dostupné z: https://doi.org/10.3892/or.2015.4533.

@article{1320448,
   author = {Šmardová, Jana and Lišková, Květoslava and Ravčuková, Barbora and Malčíková, Jitka and Hausnerová, Jitka and Svitáková, Miluše and Hrabálková, Renata and Zlámalíková, Lenka and Staňo Kozubík, Kateřina and Blaháková, Ivona and Špeldová, Jana and Jarkovský, Jiří and Šmarda, Jan},
   article_number = {3},
   doi = {https://doi.org/10.3892/or.2015.4533},
   keywords = {lung adenocarcinoma; p53 tumor suppressor; FASAY; FISH; TP53 mutation},
   language = {eng},
   issn = {1021-335X},
   journal = {Oncology Reports},
   title = {Complex analysis of the p53 tumor suppressor in lung carcinoma},
   volume = {35},
   year = {2016}
}

TY  - JOUR
ID  - 1320448
AU  - Šmardová, Jana - Lišková, Květoslava - Ravčuková, Barbora - Malčíková, Jitka - Hausnerová, Jitka - Svitáková, Miluše - Hrabálková, Renata - Zlámalíková, Lenka - Staňo Kozubík, Kateřina - Blaháková, Ivona - Špeldová, Jana - Jarkovský, Jiří - Šmarda, Jan
PY  - 2016
TI  - Complex analysis of the p53 tumor suppressor in lung carcinoma
JF  - Oncology Reports
VL  - 35
IS  - 3
SP  - 1859-1867
EP  - 1859-1867
PB  - National Hellenic Research Foundation
SN  - 1021335X
KW  - lung adenocarcinoma
KW  - p53 tumor suppressor
KW  - FASAY
KW  - FISH
KW  - TP53 mutation
N2  - Lung cancer is the leading cause of cancer-related deaths worldwide. Mutations of the TP53 gene occur very frequently in lung carcinomas and they play an important role in both oncogenic transformation of lung epithelial cells and lung carcinoma progression. We determined the TP53 status in 42 samples of squamous cell lung carcinoma (SQCC) and 56 samples of lung adenocarcinoma (AC) by the functional analysis FASAY and its variant called split assay. Altogether, we detected 64 TP53 mutations in 63 patients and analyzed them by cDNA and gDNA sequencing. The TP53 mutations were found in 76.2% (32/42) of SQCC cases, and 55.4% (31/56) of ACs. Immunoblotting revealed the p53 protein accumulation in 18 samples (42.9%) among SQCC cases and 19 samples (33.9%) among AC cases. Using fluorescence in situ hybridization we detected loss of the TP53-specific 17p13.3 locus in 23 from 41 analyzed SQCC samples (56.1%) and in 20 from 54 analyzed AC samples (37.0%). We did not find any statistically significant differences in overall and disease-free survival in relation to TP53 status.
ER  -

ŠMARDOVÁ, Jana; Květoslava LIŠKOVÁ; Barbora RAVČUKOVÁ; Jitka MALČÍKOVÁ; Jitka HAUSNEROVÁ; Miluše SVITÁKOVÁ; Renata HRABÁLKOVÁ; Lenka ZLÁMALÍKOVÁ; Kateřina STAŇO KOZUBÍK; Ivona BLAHÁKOVÁ; Jana ŠPELDOVÁ; Jiří JARKOVSKÝ a Jan ŠMARDA. Complex analysis of the p53 tumor suppressor in lung carcinoma. \textit{Oncology Reports}. National Hellenic Research Foundation, 2016, roč.~35, č.~3, s.~1859-1867. ISSN~1021-335X. Dostupné z: https://doi.org/10.3892/or.2015.4533.

Přehled o publikaci